Initial ribociclib plus endocrine therapy for HR+/HER2- advanced breast cancer in pre- and postmenopausal Chinese women: Primary results from a phase 2 randomized study.

ABSTRACT:

SUBMITTER: Shao Z 

PROVIDER: S-EPMC11320080 | biostudies-literature | 2024 Aug

REPOSITORIES: biostudies-literature